Guillain-Barré syndrome associated with SARS-CoV-2 infection. A systematic review.

COVID-19 Guillain-Barré syndrome SARS-CoV-2 coronavirus 2019 disease neuropathy

Journal

European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311

Informations de publication

Date de publication:
11 2020
Historique:
received: 17 05 2020
accepted: 29 07 2020
pubmed: 7 8 2020
medline: 18 12 2020
entrez: 7 8 2020
Statut: ppublish

Résumé

Guillain-Barré syndrome (GBS) incidence can increase during outbreaks of infectious illnesses. A few cases of GBS associated with coronavirus disease 2019 (COVID-19) infection have been reported. The aim was to identify specific clinical features of GBS associated with COVID-19. PubMed, Embase and Cochrane were searched from 1 November 2019 to 17 May 2020 and included all papers with full text in English, Spanish, French or Italian, reporting original data of patients with GBS and COVID-19. Data were extracted according to a predefined protocol. A total of 18 patients reported in 14 papers were included in this review. All the patients were symptomatic for COVID-19, with cough and fever as the most frequently reported symptoms. The interval between the onset of symptoms of COVID-19 and the first symptoms of GBS ranged from -8 to 24 days (mean 9 days; median 10 days). Most of the patients had a typical GBS clinical form predominantly with a demyelinating electrophysiological subtype. Mechanical ventilation was necessary in eight (44%) patients. Two (11%) patients died. Published cases of GBS associated with COVID-19 report a sensorimotor, predominantly demyelinating GBS with a typical clinical presentation. Clinical features and disease course seem similar to those observed in GBS related to other etiologies. These results should be interpreted with caution since only 18 cases have been heterogeneously reported so far.

Identifiants

pubmed: 32757404
doi: 10.1111/ene.14462
pmc: PMC7436512
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2361-2370

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2020 European Academy of Neurology.

Références

J Neurol Neurosurg Psychiatry. 2015 Jan;86(1):115-9
pubmed: 24816419
Neurol Sci. 2020 Jun;41(6):1351-1354
pubmed: 32399950
J Med Virol. 2020 Apr;92(4):401-402
pubmed: 31950516
Neurology. 2013 Apr 30;80(18):1650-4
pubmed: 23576619
J Neurol. 2020 Jul;267(7):1877-1879
pubmed: 32333166
Neurol Neuroimmunol Neuroinflamm. 2020 Apr 29;7(4):
pubmed: 32350026
Neuroepidemiology. 2011;36(2):123-33
pubmed: 21422765
BMJ. 2020 Mar 23;368:m1165
pubmed: 32205334
Ger Med Sci. 2015 Sep 21;13:Doc16
pubmed: 26421004
Neurologia (Engl Ed). 2020 May;35(4):268-269
pubmed: 32364123
Clin Neurophysiol. 2018 Dec;129(12):2586-2593
pubmed: 30419502
Euro Surveill. 2020 Feb;25(5):
pubmed: 32046819
Vaccine. 2011 Jan 10;29(3):599-612
pubmed: 20600491
Rev Neurol (Paris). 2020 Jun;176(6):518-519
pubmed: 32359804
Rev Neurol (Paris). 2020 Jun;176(6):516-518
pubmed: 32334841
IDCases. 2020 Apr 18;20:e00771
pubmed: 32313807
Am J Respir Crit Care Med. 2020 Sep 1;202(5):756-759
pubmed: 32663409
Neurologia (Engl Ed). 2020 May;35(4):265-267
pubmed: 32364124
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
JAMA. 2020 Apr 14;323(14):1406-1407
pubmed: 32083643
J Neurol Neurosurg Psychiatry. 2018 Sep;89(9):949-954
pubmed: 29627773
Nat Rev Neurol. 2019 Nov;15(11):671-683
pubmed: 31541214
N Engl J Med. 2020 Jun 25;382(26):2574-2576
pubmed: 32302082
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Autoimmun Rev. 2020 Jun;19(6):102537
pubmed: 32251717
J Clin Neurosci. 2020 Jul;77:230-232
pubmed: 32410788
Lancet Neurol. 2020 May;19(5):383-384
pubmed: 32246917
J Med Virol. 2020 Apr;92(4):441-447
pubmed: 31994742
J Neurol Neurosurg Psychiatry. 2012 Jan;83(1):23-8
pubmed: 22010183
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Brain Behav Immun. 2020 Jul;87:111-112
pubmed: 32360440
J Peripher Nerv Syst. 2020 Jun;25(2):204-207
pubmed: 32388880
J Clin Neurosci. 2020 Jun;76:233-235
pubmed: 32312628
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
Int J Surg. 2010;8(5):336-41
pubmed: 20171303

Auteurs

P De Sanctis (P)

Department of Neurosurgery, Humanitas Clinical and Research Institute - IRCCS, Rozzano (MI), Italy.

P E Doneddu (PE)

Department of Neurology, Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Institute - IRCCS, Rozzano (MI), Italy.

L Viganò (L)

Department of General Surgery, Humanitas Clinical and Research Institute - IRCCS, Rozzano (MI), Italy.

C Selmi (C)

Department of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Institute - IRCCS, Rozzano (MI), Italy.

E Nobile-Orazio (E)

Department of Neurology, Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Institute - IRCCS, Rozzano (MI), Italy.
Department of Medical Biotechnology and Translational Medicine, Milan University, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH